HealthInvest Partners’s Soleno Therapeutics SLNO Stock Holding History

HealthInvest Partners’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-90,184	Closed	-$2.21M	–	41
2026 Q1	$2.21M	Buy	90,184 +27,449	+44%	+$1.08M	0.71%	38
2025 Q4	$2.9M	Buy	62,735 +2,579	+4%	+$141K	0.93%	33
2025 Q3	$432K	Buy	60,156 +19,624	+48%	+$1.45M	1.6%	23
2025 Q2	$3.4M	Buy	40,532 +3,434	+9%	+$257K	1.45%	23
2025 Q1	$2.65M	Buy	37,098 +6,158	+20%	+$300K	1.17%	25
2024 Q4	$985K	Buy	30,940 +4,550	+17%	+$236K	0.47%	33
2024 Q3	$1.33M	Buy	+26,390	New	+$1.26M	0.63%	32

HealthInvest Partners's SLNO Position: Q2 2026 in Review

HealthInvest Partners sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 90,184 shares — an estimated $2.21M sold.

HealthInvest Partners first reported a position in SLNO in Q3 2024 and held it in 7 quarters. The position peaked at $3.4M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

HealthInvest Partners reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
HealthInvest Partners sold 90,184 Soleno Therapeutics shares in Q2 2026, an estimated $2.21M.
HealthInvest Partners first reported a position in Soleno Therapeutics in Q3 2024 and held it in 7 quarters.
HealthInvest Partners's Soleno Therapeutics position peaked at $3.4M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on HealthInvest Partners's 13F filing for Q2 2026, filed 24 Jul 2026.